Commercial in Japan

TAHO's first approved product - A patient-friendly ODF formulation of a selective serotonin 5HT₃ receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Currently marketed in Japan.

This immediate release lingual film is designed for easy administration. As an anti-emetic treatment that does not require swallowing. It is an ideal at-home medication for the treatment of chemo therapy-induced nausea side-effect.